Serum Expression Of Nse, Progrp And Cyfra21-1 In Patients With Small Cell Lung Cancer And Prognosis

Objective: To investigate the value of neuron-specific enolase (NSE), pro-gastrin-releasing peptide precursor (ProGrp) and cytokeratin-19 fragment (Cyfra21-1) in assisted diagnosis, treatment efficacy monitoring and prognosis evaluation of small cell lung cancer (SCLC) patients. Methods: The subjects were divided into an observation group (patients with SCLC, n = 86), a control group (patients with benign lung disease, n = 60) and normal group (healthy individuals, n = 80). The observation group was treated with EP chemotherapy regimen for two cycles (etoposide 80 mg/m(2) daily for 1-5 days and cisplatin 100 mg/m(2) for 3 or 4 days). Results: The serum expressions of NSE, ProGrp and Cyfra21-1 were detected before and after treatment. The serum expression of NSE, ProGrp and Cyfra21-1 in the observation group were significantly higher than those in the control group and normal group (all P<0.05). The expression levels of NSE, ProGrp and Cyfra21-1 in patients of extensive disease stage were significantly higher than those in patients of limited disease stage (all P<0.05). Spearman test showed that all indicators decreased with the improvement of clinical efficacy (all P<0.05). Conclusion: Univariate and multivariate Cox regression analysis found that NSE, ProGrp, Cyfra21-1, metastasis and stage were independent prognostic factors of SCLC patients. Cyfra21-1, ProGrp and NSE are highly expressed in SCLC and their expression levels are associated with clinical stage and prognosis. The serum expression of Cyfra21-1, ProGrp and NSE is negatively correlated with the therapeutic efficacy, suggesting their values are important in the monitoring of SCLC treatment.